Arcutis Biotherapeutics, Inc. (ARQT)
NasdaqGS
Price as at 30 Sept 2026, 16:06 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Arcutis Biotherapeutics, Inc. trades at $27.17. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
10 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- D. E. Shaw, D. E. Shaw & Co., Inc.$103.56M · 0.1% of book
- Ken Griffin, CITADEL ADVISORS LLC$30.42M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$17.41M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$14.79M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$11.72M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in ARQT
Trades in ARQT disclosed by members of Congress and executive-branch officials, latest first:
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 29 May 2026 · disclosed 8 Jun 2026
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 3 Mar 2026 · disclosed 7 Apr 2026
- Gilbert Cisneros · HouseSell · $1,001 - $15,000 · traded 11 Dec 2025 · disclosed 12 Jan 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own ARQT?
10 of the institutions we track reported a position in ARQT in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its ARQT data?
Fundamentals for ARQT come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:06 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ARQT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.